Pertussis immunity in pregnant women and factors associated with seronegative status

Cover Page


Cite item

Full Text

Abstract

Despite high level of vaccination coverage, pertussis remains a serious problem of modern medicine. Pertussis cases are registered among infants, adolescents, and adults. Infants younger than three months of age have the highest rate of serious clinical pertussis course. Transplacental transfer of pertussis-specific antibodies induce protection against infection. The available data regarding anti-pertussis antibody level in pregnant women in Russia remain sparce. To evaluate the humoral immunity to Bordetella pertussis in pregnant women and factors associated with seronegative status, we performed a cross-sectional study with 388 participants. SeroPertussis IgG (Israel) ELISA kit was used to quantitate antibodies against pertussis toxin/hemagglutinin. Binary logistic regression analysis was performed to assess factors associated with seronegative status. The median age of the subjects was 30 years old, more than half of which (51.3%) provided no verified pertussis vaccination data so that their children will not receive transplacental anti-infectious immunity. Gestational age was significantly associated with seronegative status. Compared to women tested during the first trimester, participants in the third trimester of pregnancy were more likely to be seronegative against pertussis. The odds of being susceptible rose with increased gestational period (p < 0.01 for linear trend). Age, number of pregnancies and vaccination status revealed no impact on significant differences between seropositive and seronegative subjects. Pertussis booster vaccinations for preschool children, adolescents and healthcare workers dealing with pregnant women and neonates as well as cocoon vaccination strategy and vaccination during pregnancy were necessary to be implemented to protect infants against pertussis.

About the authors

E. A. Krieger

Northern State Medical University

Author for correspondence.
Email: kate-krieger@mail.ru

Ekaterina A. Krieger - PhD (Medicine), Associate Professor, Department of Infectious Diseases.

163000, Arkhangelsk, Troitski pr., 51, Phone: +7 (950) 963-57-11 (mobile)

Russian Federation

O. V. Samodova

Northern State Medical University

Email: kate-krieger@mail.ru

PhD, MD (Medicine), Head of the Department of Infectious Diseases.

Arkhangelsk

Russian Federation

L. V. Titova

Northern State Medical University

Email: kate-krieger@mail.ru

PhD, MD (Medicine), Professor, Department of Infectious Diseases.

Arkhangelsk

Russian Federation

References

  1. Бабаченко И.В., Нестерова Ю.В., Чернышова Ю.Ю., Карасев В.В., Починяева Л.М., Калисникова Е.Л. Клиникоэпидемиологические аспекты коклюша у детей в условиях массовой вакцинопрофилактики // Журнал инфектологии. 2019. Т. 11, № 2. С. 88—96. doi: 10.22625/2072-6732-2019-11-2-88-96
  2. Басов А.А., Цвиркун О.В., Герасимова А.Г., Зекореева А.Х. Проблема коклюша в некоторых регионах мира // Инфекция и иммунитет. 2019. Т. 9, № 2. С. 354—362. doi: 10.15789/2220-7619-2019-2-354-362
  3. Краснов В.В., Ильяненков К.Ф., Павлович Л.Р., Кузмичева М.В. Коклюш у детей первого года жизни // Детские инфекции. 2018. Т. 17, № 1. С. 12—17. doi: 10.22627/2072-8107-2018-17-1-12-17
  4. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2018 году: Государственный доклад. М.: Роспотребнадзор, 2019. 254 c.
  5. Таточенко В.К. Коклюш — недоуправляемая инфекция // Вопросы современной педиатрии. 2014. T. 13, № 2. С. 78—82. doi: 10.15690/vsp.v13i2.975
  6. Харит С.М., Воронина О.Л., Лакоткина Е.А., Черняева Т.В. Специфическая профилактика коклюша: проблемы и перспективы // Вопросы современной педиатрии. 2007. Т. 6, № 2. С. 71—77.
  7. Abu Raya B., Srugo I., Kesse A. The decline of pertussis-specific antibodies after tetanus, diphtheria, and acellular pertussis immunization in late pregnancy. J. Infect. Dis., 2015, vol. 212, pp. 1869-1873. doi: 10.1093/infdis/jiv324
  8. BarkoffA.M., Grondahl-Yli-Hannuksela K., He Q. Seroprevalence studies of pertussis: what have we learned from different immunized populations. Pathogens and Disease, vol. 73, no. 7, pp. 1-11. doi: 10.1093/femspd/ftv050
  9. Fallo A., Manonelles G., Hozbor D., Lara C., Huespe M., Mazzeo S., Canle O., Galas M., Lopez E. Pertussis seroprevalence in adults, post-partum women and umbilical cord blood. Arch. Argent. Pediatr., 2014, vol. 112, no. 4, pp. 315-322. doi: 10.5546/aap.2014.315
  10. Hashemi S.H., Zamani M., Mamani M., Javedanpoor R., Rahighi A.H., Nadi E. Seroprevalence of Bordetella pertussis antibody in pregnant women in Iran. J. Res. Health. Sci., 2014, vol. 14, no. 2, pp. 128-131.
  11. Healy C.M., Munoz F.M., Rench M.A., Halasa N.B., Edwards K.M., Baker C.J. Prevalence of pertussis antibodies in maternal delivery, cord and infant serum. J. Infect. Dis., 2004, vol. 190, pp. 335-340. doi: 10.1086/421033
  12. Huygen K., Rodeghiero C., Govaerts D., Leroux-Roels I., Melin P., Reynders M., Van Der Meeren S., Van Den Wijngaert S., Pierard D. Bordetella pertussis seroprevalence in Belgian adults aged 20—39 years, 2012. Epidemiol. Infect., 2014, vol. 142, pp. 724728. doi: 10.1017/S0950268813002458
  13. Kilgore P.E., Salim A.M., Zervos M.J., Schmitt H.J. Pertussis: microbiology, disease, treatment, and prevention. Clin. Microbiol. Rev., 2016, vol. 29, no. 3, pp. 449-486. doi: 10.1128/CMR.00083-15
  14. Malek A., Sager R., Kuhn P. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol.,1996, vol. 36, pp. 248-255. doi: 10.1111/j.1600-0897.1996.tb00172.x
  15. Marchi S., Viviani S., Montomoli E., Trombetta C.M. Low prevalence of antibodies against pertussis in pregnant women in Italy. Lancet. Infect. Dis., 2019, vol. 19, no. 7: P690. doi: 10.1016/S1473-3099(19)30269-5
  16. Meng Q., Liu Y., Yu J., Li L., Shi W., Shen Y., Li L., Zhan S., Yang F., Wang Y., Yao K. Seroprevalence of maternal and cord antibodies specific for diphtheria, tetanus, pertussis, measles, mumps and rubella in Shunyi, Beijing. Sci. Rep., 2018, 8: 13021. doi: 10.1186/s12887-019-1860-5
  17. Mooi F.R., de Greeff S.C. The case for maternal vaccination against pertussis Lancet Infect. Dis., 2007, vol. 7, pp. 614-624. doi: 10.1016/S1473-3099(07)70113-5
  18. Naidu M.A., Muljadi R., Davies-Tuck M.L., Wallace E.M., Giles M.L. The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study. Obstet. Gynecol., 2016, vol. 215, no. 2, pp. 237.e1-237.e6. doi: 10.1016/j.ajog.2016.03.002
  19. Palmeira P., Quinello C., Silveira-Lessa A.L. IgG Placental transfer in healthy and pathological pregnancies. Clin. Dev. Immunol., 2012, 2012: 985646. doi: 10.1155/2012/985646
  20. Van Rie A., Wendelboe A.M., Englund J.A. Role of maternal pertussis antibodies in infants. Pediatr. Infect. Dis. J., 2005, vol. 24, no. 5, pp. 62-65. doi: 10.1097/01.inf.0000160915.93979.8f
  21. WHO. Pertussis vaccines: WHO position paper — August 2015. Geneva: WHO; 2015. URL: https://www.who.int/immunization/policy/position_papers/pertussis/en
  22. Wiley K.E. Sources of pertussis infection in young infants: a review of key evidence informing targeting of the cocoon strategy. Vaccine, 2013, vol. 31, pp. 618-625. doi: 10.1016/j.vaccine.2012.11.052

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Krieger E.A., Samodova O.V., Titova L.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies